These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9128799)

  • 1. Acute decrease in plasma potassium concentration following intravenous mannitol as a result of hemodilution in stable chronic hemodialysis patients.
    Swan AM; DeVita MV; Michelis MF
    Clin Nephrol; 1997 Apr; 47(4):276-7. PubMed ID: 9128799
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sodium and potassium concentration in the erythrocytes of patients undergoing chronic hemodialysis. (II).--Effects of extracellular fluid sodium concentration on the erythrocytes sodium and potassium concentration (author's transl)].
    Imada A; Horiuchi A; Kawauchi Y; Kogi Y
    Rinsho Byori; 1982 Feb; 30(2):199-203. PubMed ID: 7087241
    [No Abstract]   [Full Text] [Related]  

  • 3. [Sodium and potassium concentrations in the erythrocytes of patients undergoing chronic hemodialysis. (I)--Effects of hemodialysis on the erythrocyte sodium and potassium concentrations (author's transl)].
    Imada A; Horiuchi A; Kawauchi Y; Kogi Y
    Rinsho Byori; 1982 Jan; 30(1):82-6. PubMed ID: 7087235
    [No Abstract]   [Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sodium and potassium content of erythrocytes at the terminal stage of chronic renal insufficiency and during treatment by chronic hemodialysis].
    Terekhov NT; Goligorskiĭ MS; Kremen' MG; Vasilenko VK
    Urol Nefrol (Mosk); 1974; (6):10-4. PubMed ID: 4141153
    [No Abstract]   [Full Text] [Related]  

  • 6. [Changes in plasma aldosterone during hemodialysis in patients with terminal kidney insufficiency].
    Schnurr E; Küppers H; Higashi F; Grabensee B
    Med Welt; 1975 Sep; 26(38):1728-30. PubMed ID: 1186467
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of chronic hemodialysis on the copper and zinc trace element content in the blood in chronic renal insufficiency].
    Golod EA; Chudnovskaia MV; Makhlin NV
    Urol Nefrol (Mosk); 1976; (6):50-3. PubMed ID: 1006882
    [No Abstract]   [Full Text] [Related]  

  • 8. [Correction of acid-base imbalance in patients with chronic renal failure during hemodialysis].
    Khodas MIa; Piatnitskaia GKh; Levitskiĭ ER; Sagalovich GM; Petrosova MA
    Klin Med (Mosk); 1974 Mar; 52(3):47-53. PubMed ID: 4466949
    [No Abstract]   [Full Text] [Related]  

  • 9. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The technological progress in haemodialysis: potassium profiling].
    Kes P; Racki S; Basić-Jukić N; Ratković-Gusić I
    Acta Med Croatica; 2008; 62 Suppl 1():12-6. PubMed ID: 18578327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis.
    Migliacci R; Falcinelli F; Imperiali P; Floridi A; Nenci GG; Gresele P
    Ital Heart J; 2004 May; 5(5):371-7. PubMed ID: 15185901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.
    Kaisar MO; Wiggins KJ; Sturtevant JM; Hawley CM; Campbell SB; Isbel NM; Mudge DW; Bofinger A; Petrie JJ; Johnson DW
    Am J Kidney Dis; 2006 May; 47(5):809-14. PubMed ID: 16632019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How should dialysis fluid be individualized for the chronic hemodialysis patient? Potassium.
    Rachoin JS; Weisberg LS
    Semin Dial; 2008; 21(3):223-5. PubMed ID: 18363596
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma.
    Nielsen VG
    J Heart Lung Transplant; 2006 Nov; 25(11):1344-52. PubMed ID: 17097499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of continuous blood volume monitoring.
    Lopot F
    EDTNA ERCA J; 1996; 22(4):7-11. PubMed ID: 10723339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of the proteins of the blood plasma in the homeostasis of its amylase and pepsinogen].
    Korot'ko GF; Iuabova EIu; Vepritskaia EA
    Fiziol Zh Im I M Sechenova; 1993 Apr; 79(4):61-7. PubMed ID: 7689903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dangers of repeated perfusions of mannitol in patients with renal insufficiency].
    Bonsom R; Bourdais A; Thire P
    Anesth Analg (Paris); 1970; 27(5):843-54. PubMed ID: 5481450
    [No Abstract]   [Full Text] [Related]  

  • 18. [Probabilistic evaluation of hemodialysis influence on the concentration of some blood components].
    Baczyk K
    Med Dosw; 1967; 35():5-32. PubMed ID: 6072149
    [No Abstract]   [Full Text] [Related]  

  • 19. The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic haemodialysis patients.
    Heguilén RM; Sciurano C; Bellusci AD; Fried P; Mittelman G; Rosa Diez G; Bernasconi AR
    Nephrol Dial Transplant; 2005 Mar; 20(3):591-7. PubMed ID: 15687112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mannitol induced central nervous system toxicity in renal failure.
    Silber SJ; Thompson N
    Invest Urol; 1972 Jan; 9(4):310-2. PubMed ID: 5058770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.